Grifols, S.A. (GRFS)
SubavaliadaFundamental
76
Preço
$7.31
Capitalização de Mercado
$4.98B
Parte 1 · Quanto vale a empresa
Visão Geral
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18 de setembro de 2026 with claude-haiku-4-5 — shared with all users
A smaller US fractionator with its own donation centers whose immunoglobulin Asceniv competes for the same immunodeficiency patients and the same US plasma donors.
Its non-plasma antibody Vyvgart treats myasthenia gravis and CIDP, the neurological indications that account for a large share of Grifols' immunoglobulin revenue.
The largest plasma fractionator worldwide, it collects donor plasma in the same US centers and sells rival immunoglobulins and the alpha-1 therapy Respreeza against Grifols' Gamunex and Prolastin.
Through its BioLife donation network and its plasma-derived business, it sells a 10% liquid immunoglobulin and the alpha-1 products Aralast and Glassia to the same hospitals and specialty pharmacies Grifols supplies.
A privately held Swiss fractionator that runs its own US plasma centers and markets 5% and 10% liquid immunoglobulins competing head-on with Flebogamma and Xembify.
An Italian private plasma company selling immunoglobulins, albumin and hyperimmunes in Europe and the United States, the same product range and the same territories as Grifols' Biopharma division.
Balanço & Liquidez
Receita
$2.01B
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Resultado Líquido
$172M
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Fluxo de Caixa Livre
$573M
Capital Próprio Total
$1.20B
Passivo Total
$9.36B
Rácio de Liquidez
2.37
Cobertura de Juros
-
Dívida/EBITDA
5.69
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$12.35
Preço Atual
$7.31
Margem de Segurança
+40.8%
Intervalo de Valor Justo
$8.03 - $16.67
Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
10.99
ROE
6.9%
Rácio P/B
0.90
P/FCF
3.29
Margem Bruta
37.0%
ROIC
8.8%
Radar de Rentabilidade
Criação de Valor (Vantagem Competitiva)
ROIC
8.8%
WACC
3.6%
ROIC − WACC
+5.2 pp
O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.
Critérios de Análise Fundamental
Aprovado (16)
- ROIC 8.8%
- Gross Margin 37.0%
- P/FCF 3.29
- P/B Ratio 0.90
- Operating Margin 16.2%
- Positive Free Cash Flow
- Current Ratio
- Debt/EBITDA
- Price below Graham Number
- DCF valuation (Undervalued)
- ROE 8.4%
- Revenue Growth 5Y 7.1%
- Analyst Consensus 67% Buy
- Earnings Surprise avg 45.6%
- Earnings Quality (OCF/NI) 2.71
- Net Margin Trend 5.3% vs 2.2%
Reprovado (4)
- Price CAGR -7.72%
- Debt/Equity ratio
- CapEx intensity
- Piotroski F-Score 2/9
Indisponível (7)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Participações institucionais
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Jose Ignacio Abia Buenache | CEO & Director | 57 |
| Mr. Rahul Srinivasan | Chief Financial Officer | 48 |
| Mr. Lluis Pons Gomez | Senior Vice President of Strategy & COO Office | 41 |
| Daniel Segarra | Head of Investor Relations & Sustainability and Vice President | - |
| Mr. David Ian Bell | Chief Corporate Affairs & Legal Officer | 71 |
| Mr. Enrique de la Torre | Chief Compliance Officer | 52 |
| Ms. Montse Ribas | Chief Communications and Reputation Officer | 56 |
| Mr. Camille Alpi | Chief Human Resources & Talent Officer | 44 |
| Mr. Vicente Blanquer Torre | Chief Quality Officer | 64 |
| Mr. Ignacio Ramal Subira | Chief Internal Audit & Enterprise Risk Manager | 57 |
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for GRFS, sourced from Markets Gazette.